Richard Schlenk, MD

NCT-Trial Center, National Center of Tumor Diseases, Heidelberg University Hospital and German Cancer Research Center, Heidelberg, Germany, Germany

Disclosure(s): No financial relationships to disclose

Poster(s):

• 1142 - Plasma with high titers of anti-SARS-Cov2 antibodies improves outcome of COVID-19 in patients with hematological malignancy and cancer in a randomized controlled trial
  Friday, October 21, 2022

  12:15 PM – 1:30 PM US ET